Objective: Social determinants of health (SDOH) are nonmedical factors that can influence health outcomes. This paper seeks to extract SDOH from clinical texts in the context of the National NLP Clinical Challenges (n2c2) 2022 Track 2 Task.
Materials And Methods: Annotated and unannotated data from the Medical Information Mart for Intensive Care III (MIMIC-III) corpus, the Social History Annotation Corpus, and an in-house corpus were used to develop 2 deep learning models that used classification and sequence-to-sequence (seq2seq) approaches.
The research described in this paper aimed to determine whether people respond differently to short and long stimuli and whether stress stimuli repeated over time evoke a habituation effect. To meet this goal, we performed a cognitive experiment with eight subjects. During this experiment, the subjects were presented with two trays of stress-inducing stimuli (different in length) interlaced with the main tasks.
View Article and Find Full Text PDFJ Assoc Med Microbiol Infect Dis Can
December 2019
Objectives: To review the notification rate and characteristics of tertiary and neurosyphilis cases in Alberta, Canada in the postantibiotic era.
Methods: A retrospective review of all neurosyphilis and tertiary syphilis cases reported in Alberta from 1973 to March 2017 was undertaken and cases classified into early neurosyphilis, late neurosyphilis and cardiovascular (CV) syphilis. Variables collected included demographics, sexual partners, HIV status, clinical parameters, symptoms and treatment and distributions were compared between early versus late neurosyphilis and asymptomatic versus symptomatic cases (stratified by early versus late stage).
BMJ Open
August 2016
Objectives: Persistence of human papillomaviruses (HPVs) is necessary for cervical carcinogenesis. We evaluated incidence and duration of type-specific HPV infections and the influence of age and number of sexual partners.
Methods: Data were obtained from 553 women (15-25 years), who were seronegative and DNA-negative for high-risk HPV (HR-HPV) types and were enrolled in the placebo arm of a randomised trial of the HPV-16/18 vaccine (NCT00689741/NCT00120848).